Sorry, you need to enable JavaScript to visit this website.

STELARA® for Crohn's Disease (CD) Treatment | STELARA® (ustekinumab) HCP

FOR ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CD 

*In both the CD and UC studies, many patients achieved clinical remission at 1 year with STELARA®.

FAST

6-WEEK RAPID RESPONSE: 
Many patients achieved clinical response† at Week 6 and 70-point response as early as Week 3 in clinical studies1

VIEW RESPONSE
DATA

LASTS

LASTING REMISSION: 
Many patients achieved clinical remission‡ at 1 year in a clinical study1

VIEW REMISSION 
DATA

PROVEN

SAFETY PROFILE:
STELARA® has a proven safety profile through 1 year. Plus safety data through 5 years (from Phase 3 studies and open-label LTE)1,2

VIEW CD 
SAFETY

Resources to help your patients

Learn More

Local Coverage

Commercial Formulary Coverage Look-up

Enter Your ZIP Code to View Coverage Results

Please enter zip code  

All information is subject to change. Actual benefits determined by health plan. We strongly recommend you call the health plan for its reimbursement policies. This information does not advise on or guarantee coverage or payment.

STELARA withMe is here to support your patients

STELARA withMe provides a range of dedicated support and resources to help make it easier for patients as they begin, and continue, their STELARA® treatment journey.

Learn More

The Provider Portal JanssenCarePathPortal.com is still available. There you can request and review benefits investigations, enroll eligible patients in the STELARA withMe Savings Program, and view Savings Program transactions as requested by the patient.

CD=Crohn's disease; CDAI=Crohn's Disease Activity Index; LTE=long-term extension; UC=ulcerative colitis.

 

†Clinical response was defined as reduction in CDAI score of ≥100 points or CDAI score of <150.

‡Clinical remission was defined as a CDAI score of <150.

 

References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc.